Holen Sie sich die Stockscreener-App
1.27
1.60%
0.02
Handel nachbörslich:
1.27
Schlusskurs vom Vortag:
$1.25
Offen:
$1.25
24-Stunden-Volumen:
9,099
Relative Volume:
0.25
Marktkapitalisierung:
$62.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.51M
KGV:
-6.6842
EPS:
-0.19
Netto-Cashflow:
$-10.96M
1W Leistung:
+0.00%
1M Leistung:
-3.05%
6M Leistung:
-13.01%
1J Leistung:
-39.52%
1-Tages-Spanne:
$1.25
$1.27
1-Wochen-Bereich:
$1.23
$1.29
52-Wochen-Spanne:
$1.13
$2.55
Medicinova Inc Stock (MNOV) Company Profile
Firmenname
Medicinova Inc
Sektor
Branche
Telefon
858-373-1500
Adresse
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Vergleichen Sie MNOV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.27 | 61.31M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-10 | Eingeleitet | Maxim Group | Buy |
| 2019-03-25 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-03-28 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2013-01-04 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-05-24 | Herabstufung | MLV & Co | Buy → Hold |
| 2011-10-18 | Bestätigt | MLV Capital | Buy |
| 2011-06-22 | Eingeleitet | Global Hunter Securities | Buy |
| 2010-05-12 | Eingeleitet | Wedbush | Outperform |
| 2008-11-12 | Bestätigt | Ladenburg Thalmann | Buy |
| 2008-05-15 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | Eingeleitet | Punk, Ziegel & Co | Buy |
Alle ansehen
Medicinova Inc Aktie (MNOV) Neueste Nachrichten
Can a trend reversal in MediciNova Inc. lead to recoveryMarket Sentiment Summary & Breakout Confirmation Trade Signals - newser.com
What drives MediciNova Inc stock priceAnalyst Downgrades & Small Budget Trading Ideas - earlytimes.in
MediciNova Inc. recovery potential after sell offQuarterly Performance Summary & Reliable Volume Spike Trade Alerts - newser.com
Long term hold vs stop loss in MediciNova Inc.2025 Technical Overview & Free Risk Controlled Daily Trade Plans - newser.com
Why MediciNova Inc. stock is favored by top institutions2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com
Will MediciNova Inc. stock benefit from sector rotationEarnings Recap Report & Daily Profit Focused Screening - newser.com
What MACD signals say about MediciNova Inc.2025 Major Catalysts & Daily Stock Trend Reports - newser.com
What does recent volatility data suggest for MediciNova Inc.July 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Custom strategy builders for tracking MediciNova Inc.Portfolio Value Report & AI Enhanced Trading Alerts - newser.com
Is MediciNova Inc a good long term investmentSupport and Resistance Levels & Interactive Learning for Better Returns - Early Times
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - 富途牛牛
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova completes patient enrollment in phase 2/3 ALS trial - Investing.com India
MediciNova completes patient enrollment in phase 2/3 ALS trial By Investing.com - Investing.com South Africa
MediciNova (MNOV) Maintains "Buy" Rating from D. Boral Capital | - GuruFocus
MediciNova (MNOV) Completes Enrollment for Key ALS Treatment Tri - GuruFocus
MediciNova Completes Patient Enrollment in Phase 2b/3 Trial of Ibudilast for Treatment of ALS - MarketScreener
MediciNova Announces Completion of Patient Enrollment - GlobeNewswire
MediciNova Announces Completion of Patient Enrollment in COMBAT- - GuruFocus
234 ALS Patients Enrolled: MediciNova's Fast-Track Drug Trial Could Offer New Hope for Fatal Disease - Stock Titan
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) - Yahoo Finance
Building trade automation scripts for MediciNova Inc.Weekly Volume Report & Community Shared Stock Ideas - newser.com
Gains Report: What is the next catalyst for MediciNova IncProfit Target & High Return Trade Opportunity Guides - خودرو بانک
Finanzdaten der Medicinova Inc-Aktie (MNOV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):